AI Article Synopsis
- The study investigates the effectiveness of tivantinib for treating MET-high hepatocellular carcinoma, comparing it to a placebo.
- The analysis included three randomized controlled trials, revealing that tivantinib showed no significant improvement in overall or progression-free survival compared to the control group.
- While tivantinib was linked to increased rates of severe neutropenia and leukopenia, it did not affect severe anemia rates, suggesting it may not be a beneficial treatment option for this cancer type.
Article Abstract
Background: The efficacy of tivantinib for MET-high hepatocellular carcinoma remains controversial. We conduct this meta-analysis to explore the efficacy of tivantinib versus placebo for MET-high hepatocellular carcinoma.
Methods: We have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through November 2022 and included randomized controlled trials (RCTs) assessing the efficacy and safety of tivantinib versus placebo for MET-high hepatocellular carcinoma.
Results: Three RCTs were included in the meta-analysis. Overall, compared with control group for MET-high hepatocellular carcinoma, tivantinib showed no obvious impact on overall survival (hazard ratio [HR] = 0.77; 95% confidence interval [CI] = 0.52-1.13; P = .18) or progression-free survival (HR = 0.78; 95% CI = 0.56-1.08; P = .14). In addition, tivantinib was associated with the increase in grade ≥3 neutropenia (odd ratio [OR] = 11.76; 95% CI = 2.77-49.89; P = .0008) and leukopenia (OR = 14; 95% CI = 1.68-116.82; P = .01), but demonstrated no impact on the incidence of grade ≥ 3 anemia (OR = 2.74; 95% CI = 0.14-53.43; P = .51).
Conclusions: Tivantinib may not benefit to the treatment of MET-high hepatocellular carcinoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118349 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000032591 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Stable self-assembled oral metformin-bridged nanocochleates against hepatocellular carcinoma.
Drug Deliv Transl Res
November 2024
Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt.
Despite its established anti-diabetic activity, Metformin hydrochloride (MET) has been repurposed for the management of hepatocellular carcinoma (HCC). Owing to MET high aqueous solubility and poor oral permeability, a novel nanoplatform is sought to overcome the current challenges of traditional formulations. In this study, we developed MET-bridged nanocochleates (MET-CO) using a direct bridging method followed by optimization and assessment using various in-vitro and in-vivo pharmacokinetic methods.
View Article and Find Full Text PDFThe effectiveness of tivantinib for MET-high hepatocellular carcinoma: A protocol for meta analysis.
Medicine (Baltimore)
April 2023
Department of Hepatology, Chongqing Traditional Chinese Medicine Hospital, Chongqing, China.
Article Synopsis
- The study investigates the effectiveness of tivantinib for treating MET-high hepatocellular carcinoma, comparing it to a placebo.
- The analysis included three randomized controlled trials, revealing that tivantinib showed no significant improvement in overall or progression-free survival compared to the control group.
- While tivantinib was linked to increased rates of severe neutropenia and leukopenia, it did not affect severe anemia rates, suggesting it may not be a beneficial treatment option for this cancer type.
MYC and MET cooperatively drive hepatocellular carcinoma with distinct molecular traits and vulnerabilities.
Cell Death Dis
November 2022
Aix-Marseille Univ, CNRS, Developmental Biology Institute of Marseille (IBDM), Turing Center for Living Systems, Parc Scientifique de Luminy, Marseille, France.
Enhanced activation of the transcription factor MYC and of the receptor tyrosine kinase MET are among the events frequently occurring in hepatocellular carcinoma (HCC). Both genes individually act as drivers of liver cancer initiation and progression. However, their concomitant alteration in HCC has not been explored, nor functionally documented.
View Article and Find Full Text PDFApplication of Tivantinib for Hepatocellular Carcinoma: A Meta-Analysis Study.
Evid Based Complement Alternat Med
June 2022
Key Laboratory for Biorheological Science and Technology of Ministry of Education (Chongqing University), Chongqing University Cancer Hospital, Chongqing 400044, China.
Article Synopsis
- The study investigates the effectiveness of tivantinib compared to a placebo in treating MET-high hepatocellular carcinoma.
- Researchers conducted a systematic review of multiple databases up to March 2022, focusing on randomized controlled trials (RCTs) involving tivantinib.
- The results indicate that tivantinib does not significantly improve overall survival or other key outcomes compared to placebo, but it does increase the risk of severe neutropenia.
c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells and .
J Biomed Res
December 2021
National Health Commission Key Laboratory of Antibody Techniques, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
c-Met is a hepatocyte growth factor receptor overexpressed in many tumors such as hepatocellular carcinoma (HCC). Therefore, c-Met may serve as a promising target for HCC immunotherapy. Modifying T cells to express c-Met-specific chimeric antigen receptor (CAR) is an attractive strategy in treating c-Met-positive HCC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!